Denys-Drash syndrome (DDS) is characterized by nephropathy, genital abnormalities, and predisposition to Wilms' tumor. DDS patients usually present heterozygous de novo germline WT1 mutations. The WT1 gene comprises 10 exons encoding the N-terminal transactivation and the C-terminal DNA-binding regions. Two unrelated patients with genital ambiguity and Wilms' tumor were analyzed by sequencing of the WT1 gene, and 3 mutations in exon 1 were identified of which 2 are novel. Patient 1 carried a c.555delC mutation that causes a frameshift and a premature stop codon. Patient 2 carried both c.421A>C and c.424C>T aberrations that lead to the missense p.Lys141Gln and the nonsense p.Lys142* mutation, respectively. As both patients were heterozygous for the mutations, we tested their parents who did not carry any mutation. Therefore, the 3 WT1 mutations occurred de novo in both patients. Heterozygous mutations result in WT1 haploinsufficiency as they impair protein production. They are associated with a milder DDS phenotype as observed in the patients studied here.

1.
Adzhubei IA, Schmidt S, Peshkin L, Ramensky VE, Gerasimova A, et al: A method and server for predicting damaging missense mutations. Nat Methods 7:248-249 (2010).
2.
Bardeesy N, Zabel B, Schmitt K, Pelletier J: WT1 mutations associated with incomplete Denys-Drash syndrome define a domain predicted to behave in a dominant-negative fashion. Genomics 21:663-664 (1994).
3.
Bruening W, Bardeesy N, Silverman BL, Cohn RA, Machin GA, et al: Germline intronic and exonic mutations in the Wilms' tumour gene (WT1) affecting urogenital development. Nat Genet 1:144-148 (1992).
4.
Call KM, Glaser T, Ito CY, Buckler AJ, Pelletier J, et al: Isolation and characterization of a zinc finger polypeptide gene at the human chromosome 11 Wilms' tumor locus. Cell 60:509-520 (1990).
5.
Coppes MJ, Huff V, Pelletier J: Denys-Drash syndrome: relating a clinical disorder to genetic alterations in the tumor suppressor gene WT1. J Pediatr 123:673-678 (1993).
6.
Denys P, Malvaux P, Van Den Berghe H, Tanghe W, Proesmans W: Association of an anatomo-pathological syndrome of male pseudohermaphroditism, Wilms' tumor, parenchymatous nephropathy and XX/XY mosaicism (in French). Arch Fr Pediatr 24:729-739 (1967).
7.
Drash A, Sherman F, Hartmann WH, Blizzard RM: A syndrome of pseudohermaphroditism, Wilms' tumor, hypertension, and degenerative renal disease. J Pediatr 76:585-593 (1970).
8.
Eneman B, Mekahli D, Audrezet M-P, Lerut E, Van Damme-Lombaerts R, et al: An unusual presentation of Denys-Drash syndrome due to bigenic disease. Pediatrics 133:e252-e256 (2014).
9.
Gessler M, Poustka A, Cavenee W, Neve RL, Orkin SH, Bruns GAP: Homozygous deletion in Wilms tumors of a zinc-finger gene identified by chromosome jumping. Nature 343:774-778 (1990).
10.
Haber DA, Sohn RL, Buckler A, J Pelletier J, Call KM, Housman DE: Alternative splicing and genomic structure of the Wilms tumor gene WT1. Proc Natl Acad Sci USA 88:9618-9622 (1991).
11.
Holmes G, Boterashvili S, English M, Wainwright B, Licht J, Little M: Two N-terminal self-association domains are required for the dominant negative transcriptional activity of WT1 Denys-Drash mutant proteins. Biochem Biophys Res Commun 233:723-728 (1997).
12.
Huff V, Jaffe N, Saunders GF, Strong LC, Villalba F, Ruteshouser EC: WT1 exon 1 deletion/insertion mutations in Wilms tumor patients, associated with di- and trinucleotide repeats and deletion hotspot consensus sequences. Am J Hum Genet 56:84-90 (1995).
13.
Jeanpierre C, Denamur E, Henry I, Cabanis MO, Luce S, et al: Identification of constitutional WT1 mutations, in patients with isolated diffuse mesangial sclerosis, and analysis of genotype/phenotype correlations by use of a computerized mutation database. Am J Hum Genet 62:824-833 (1998).
14.
Koziell AB, Grundy R, Barratt TM, Scambler P: Evidence for the genetic heterogeneity of nephropathic phenotypes associated with Denys-Drash and Frasier syndromes. Am J Hum Genet 64:1778-1781 (1999).
15.
Kumar P, Henikoff S, Ng PC: Predicting the effects of coding non-synonymous variants on protein function using the SIFT algorithm. Nat Protoc 4:1073-1081 (2009).
16.
Little M, Holmes G, Bickmore W, van Heyningen V, Hastie N, Wainwright B: DNA binding capacity of the WT1 protein is abolished by Denys-Drash syndrome WT1 point mutations. Hum Mol Genet 4:351-358 (1995).
17.
Little SE: Frequency and heritability of WT1 mutations in nonsyndromic Wilms' tumor patients: a UK children's cancer study group study. J Clin Oncol 22:4140-4146 (2004).
18.
Little SE, Hanks S, King-Underwood L, Picton S, Cullinane C, et al: A WT1 exon 1 mutation in a child diagnosed with Denys-Drash syndrome. Pediatr Nephrol 20:81-85 (2005).
19.
Ottens F, Gehring NH: Physiological and pathophysiological role of nonsense-mediated mRNA decay. Pflugers Arch 468:1013-1028 (2016).
20.
Pelletier J, Bruening W, Li FP, Haber DA, Glaser T, Housman DE: WT1 mutations contribute to abnormal genital system development and hereditary Wilms' tumour. Nature 353:431-434 (1991a).
21.
Pelletier J, Bruening W, Kashtan CE, Mauer SM, Manivel JC, et al: Germline mutations in the Wilms' tumor suppressor gene are associated with abnormal urogenital development in Denys-Drash syndrome. Cell 67:437-447 (1991b).
22.
Pritchard-Jones K, Fleming S, Davidson D, Bickmore W, Porteous D, et al: The candidate Wilms' tumour gene is involved in genitourinary development. Nature 346:194-197 (1990).
23.
Regev M, Kirk R, Mashevich M, Bistritzer Z, Reish O: Vertical transmission of a mutation in exon 1 of the WT1 gene: lessons for genetic counseling. Am J Med Genet A 146A:2332-2336 (2008).
24.
Sambrook J, Fritsch EF, Maniatis T: Molecular Cloning: A Laboratory Manual (Cold Spring Harbor Laboratory Press, Cold Spring Harbor 1989).
25.
Sharma PM, Bowman M, Madden SL, Rauscher FJ, Sukumar S: RNA editing in the Wilms' tumor susceptibility gene, WT1. Genes Dev 8:720-731 (1994).
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.